2024年1至12月份，康为世纪的营业收入构成为：分子诊断行业占比100.0%。 截至发稿，康为世纪市值为26亿元。 延伸阅读： 中化岩土王立肖辞去公司内部审计负责人职务 嘉应制药:聘任蒋坤为公司内部审计负责人 景谷林业聘任梁丽华担任公司内部审计负责人 原标题："康为世纪：拟聘任汤玉峰为公司内部审计负责人" 每经AI快讯，康为世纪（SH 688426）7月28日晚间发布公告称，经公司董事会审计委员会提名，审议 通过《关于聘任公司内部审计负责人的议案》，公司拟聘任汤玉峰先生为公司内部审计负责人。 ...

Core Viewpoint - Cardiff Oncology (CRDF) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system emphasizes the importance of earnings estimate revisions, which are strongly correlated with near-term stock price movements [4][6]. - Rising earnings estimates for Cardiff Oncology suggest an improvement in the company's underlying business, potentially leading to higher stock prices [5]. Recent Earnings Estimate Revisions - For the fiscal year ending December 2025, Cardiff Oncology is expected to earn -$0.82 per share, reflecting a 13.7% change from the previous year [8]. - Over the past three months, the Zacks Consensus Estimate for Cardiff Oncology has increased by 13.1%, indicating a positive trend in earnings expectations [8]. Zacks Rank System Overview - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 (Strong Buy) stocks historically generating an average annual return of +25% since 1988 [7]. - The upgrade of Cardiff Oncology to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [10].